# EDGAR Filing Document

**Accession Number:** 0001851484
**File Stem:** 0001213900-25-089630
**Filing Date:** 2025-9
**Character Count:** 28879
**Document Hash:** 93a146c1a27ca629421b65d0178526c3
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-089630.hdr.sgml**: 20250919

**ACCESSION NUMBER**: 0001213900-25-089630

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 14

**FILED AS OF DATE**: 20250919

**DATE AS OF CHANGE**: 20250919

**EFFECTIVENESS DATE**: 20250919

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CITIUS ONCOLOGY, INC.
- **CENTRAL INDEX KEY:** 0001851484
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 994362660
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0930

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-290417
- **FILM NUMBER:** 251327623

**BUSINESS ADDRESS:**
- **STREET 1:** 11 COMMERCE DRIVE
- **STREET 2:** 1ST FLOOR
- **CITY:** CRANFORD
- **STATE:** NJ
- **ZIP:** 07016
- **BUSINESS PHONE:** (908) 967-6677

**MAIL ADDRESS:**
- **STREET 1:** 11 COMMERCE DRIVE
- **STREET 2:** FIRST FLOOR
- **CITY:** CRANFORD
- **STATE:** NJ
- **ZIP:** 07016

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** TenX Keane Acquisition
- **DATE OF NAME CHANGE:** 20210315

**As filed with the Securities and Exchange Commission on September 19** **, 2025**

**Registration No. 333-** 

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

**FORM S-8**

**REGISTRATION STATEMENT**

**UNDER THE SECURITIES ACT OF 1933**

 **CITIUS ONCOLOGY, INC.**

(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **Delaware** | **99-4362660** |
| (State or other jurisdiction of<br> incorporation or organization) | (I.R.S. Employer <br> Identification No.) |

---

---

| | |
|:---|:---|
| **11 Commerce Drive, First Floor, Cranford New Jersey** | **07016** |
| (Address of principal executive offices) | (Zip code) |

---

**Citius Oncology, Inc. 2023 Omnibus Stock Incentive Plan**

**Citius Oncology, Inc. 2024 Omnibus Stock Incentive Plan**

(Full title of the plans)

**Leonard Mazur**

**Chairman and Chief Executive Officer** 

**11 Commerce Drive, First Floor**

**Cranford, New Jersey 07016** 

**Telephone: (908) 967-6677**

(Name and address of agent for service) (Telephone number, including area code, of agent for service)

***With copies to:***

**Lorna A. Knick, Esq.** 

**Alexander M. Donaldson, Esq.** 

**Christopher P. Agoranos, Esq.** 

**Wyrick Robbins Yates & Ponton LLP** 

**4101 Lake Boone Trail, Suite 300** 

**Raleigh, North Carolina 27607** 

**Telephone: (919) 781-4000**

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐ <br> Non-accelerated filer ☒ Smaller reporting company ☒ <br> Emerging growth company ☒

If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

**PART I**

**INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS**

**Item 1. Plan Information.**

Information required by Item 1 is included in documents sent or given by Citius Oncology, Inc. (the "Registrant") to participants in the 2023 Omnibus Stock Incentive Plan or the 2024 Omnibus Stock Incentive Plan (collectively, the "Plans"), as applicable, as covered by this Registration Statement pursuant to Rule 428(b)(1) of the Securities Act of 1933, as amended (the "Securities Act").

**Item 2. Registrant Information and Employee Plan Annual Information.**

The written statement required by Item 2 is included in documents sent or given by the Registrant to participants in the Plans covered by this Registration Statement pursuant to Rule 428(b)(1) of the Securities Act.

**PART II**

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

**Item 3. Incorporation of Documents by Reference**.

The following documents filed with the Securities and Exchange Commission (the "Commission") are hereby incorporated by reference in this Registration Statement (other than portions of those documents furnished or otherwise not deemed filed):

● the Registrant's Annual Report on [Form 10-K](http://www.sec.gov/ix?doc=/Archives/edgar/data/1851484/000121390024113150/ea0225372-10k_citius.htm) for the fiscal year ended September 30, 2024, filed with the Commission on December 27, 2024, as amended on [January 27, 2025;](http://www.sec.gov/ix?doc=/Archives/edgar/data/1851484/000121390025007012/ea0228749-10ka1_citius.htm)

● the Registrant's Quarterly Report on [Form 10-Q](http://www.sec.gov/Archives/edgar/data/1851484/000121390025014320/ea0230776-10q_citius.htm) for the fiscal quarter ended December 31, 2024, filed with the Commission pursuant to Section 13(a) of the Exchange Act on February 14, 2025;

● the Registrant's Quarterly Report on [Form 10-Q](http://www.sec.gov/Archives/edgar/data/1851484/000121390025043359/ea0241639-10q_citius.htm) for the fiscal quarter ended March 31, 2025, filed with the Commission pursuant to Section 13(a) of the Exchange Act on May 14, 2025;

● the Registrant's Quarterly Report on [Form 10-Q](http://www.sec.gov/Archives/edgar/data/1851484/000121390025074992/ea0252318-10q_citius.htm) for the fiscal quarter ended June 30, 2025, filed with the Commission pursuant to Section 13(a) of the Exchange Act on August 12, 2025;

● the Registrant's Current Reports on Form 8-K, filed with the Commission on [November 12, 2024,](http://www.sec.gov/ix?doc=/Archives/edgar/data/1851484/000121390024096269/ea0220666-8k_citius.htm) and [January 6,](http://www.sec.gov/ix?doc=/Archives/edgar/data/1851484/000121390025000953/ea0226665-8k_citius.htm) [January 7, 2025,](http://www.sec.gov/ix?doc=/Archives/edgar/data/1851484/000121390025001407/ea0226984-8k_citius.htm) [February 6,](http://www.sec.gov/ix?doc=/Archives/edgar/data/1851484/000121390025010748/ea0230157-8k_citius.htm) [February 14,](http://www.sec.gov/ix?doc=/Archives/edgar/data/1851484/000121390025014351/ea0231246-8k_citius.htm) [April 3,](http://www.sec.gov/ix?doc=/Archives/edgar/data/1851484/000121390025028621/ea0237095-8k_citius.htm) [April 25,](http://www.sec.gov/ix?doc=/Archives/edgar/data/1851484/000121390025035575/ea0239433-8k_citius.htm) [June 17,](http://www.sec.gov/ix?doc=/Archives/edgar/data/1851484/000121390025055182/ea0245933-8k_citius.htm) [June 27,](http://www.sec.gov/ix?doc=/Archives/edgar/data/1851484/000121390025059084/ea024719201-8k_citius.htm) [July 18,](http://www.sec.gov/ix?doc=/Archives/edgar/data/1851484/000121390025065334/ea0249292-8k_citius.htm) [August 18,](http://www.sec.gov/ix?doc=/Archives/edgar/data/1851484/000121390025078018/ea0253763-8k_citius.htm) [September 10,](http://www.sec.gov/ix?doc=/Archives/edgar/data/1851484/000121390025086568/ea0256723-8k_citius.htm) and [September 19, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1851484/000121390025089615/ea0257909-8k_citius.htm) ; and

● the description of the Company's Common Stock contained in the Registration Statement on [Form 8-A](http://www.sec.gov/Archives/edgar/data/1851484/000149315222028299/form8-a12b.htm) (File No. 001-41534), filed with the SEC under Section 12(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act") on October 13, 2022, as updated by the description of the Registrant's common stock contained in [Exhibit 4.2](http://www.sec.gov/Archives/edgar/data/1851484/000121390024113150/ea022537201ex4-2_citius.htm) to the Registrant's Annual Report on Form 10-K for the year ended September 30, 2024, filed with the SEC on December 27, 2024, including any amendments or reports filed for the purpose of updating such description.

In addition, all documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a post-effective amendment which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of filing of such documents. However, any documents or portions thereof, whether specifically listed above or filed in the future, that are not deemed "filed" with the Commission, including without limitation any information furnished pursuant to Item 2.02 or 7.01 of Form 8-K or certain exhibits furnished pursuant to Item 9.01 of Form 8-K, shall not be deemed to be incorporated by reference in this Registration Statement.

Any statement in a document incorporated by reference or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for the purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is incorporated or deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

**Item 4. Description of Securities.**

Not applicable. The class of securities to be offered is registered under Section 12 of the Exchange Act.

**Item 5. Interests of Named Experts and Counsel.**

Not applicable.

**Item 6. Indemnification of Directors and Officers.**

Subsection (a) of Section 145 of the General Corporation Law of the State of Delaware (the "DGCL") empowers a corporation to indemnify any person who was or is a party or who is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the corporation) by reason of the fact that the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys' fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with such action, suit or proceeding if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe the person's conduct was unlawful.

Subsection (b) of Section 145 empowers a corporation to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that the person acted in any of the capacities set forth above, against expenses (including attorneys' fees) actually and reasonably incurred by the person in connection with the defense or settlement of such action or suit if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation, except that no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or the court in which such action or suit was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper.

Section 145 further provides that to the extent a director or officer of a corporation has been successful on the merits or otherwise in the defense of any action, suit or proceeding referred to in subsections (a) and (b) of Section 145, or in defense of any claim, issue or matter therein, such person shall be indemnified against expenses (including attorneys' fees) actually and reasonably incurred by such person in connection therewith; that indemnification provided for by Section 145 shall not be deemed exclusive of any other rights to which the indemnified party may be entitled; and the indemnification provided for by Section 145 shall, unless otherwise provided when authorized or ratified, continue as to a person who has ceased to be a director, officer, employee or agent and shall inure to the benefit of such person's heirs, executors and administrators. Section 145 also empowers the corporation to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against such person and incurred by such person in any such capacity, or arising out of his status as such, whether or not the corporation would have the power to indemnify such person against such liabilities under Section 145.

Section 102(b)(7) of the DGCL provides that a corporation's certificate of incorporation may contain a provision eliminating or limiting the personal liability of a director to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, provided that such provision shall not eliminate or limit the liability of a director (i) for any breach of the director's duty of loyalty to the corporation or its stockholders, (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) under Section 174 of the DGCL, or (iv) for any transaction from which the director derived an improper personal benefit.

Additionally, our certificate of incorporation limits the liability of our directors to the fullest extent permitted by the DGCL, and our Bylaws provide that we will indemnify them to the fullest extent permitted by such law.

We maintain a general liability insurance policy that covers certain liabilities of directors and officers of the Company arising out of claims based on acts or omissions in their capacities as directors or officers.

**Item 7. Exemption From Registration Claimed.**

Not applicable.

**Item 8. Exhibits.**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **EXHIBIT NO.** | **DESCRIPTION** | **FILE HEREWITH** | **FORM** | **EXHIBIT** | **FILING DATE** |
| .1 | [Certificate of Incorporation of Citius Oncology, Inc.](http://www.sec.gov/Archives/edgar/data/1851484/000121390024070335/ea021142301ex3-1_citius.htm) |  | 8-K | 3.1 | 8/16/2024 |
| 4.2 | [Certificate of Amendment to the Certificate of Incorporation of Citius Oncology, Inc., filed with the Secretary of State of the State of Delaware on April 7, 2025.](http://www.sec.gov/Archives/edgar/data/1851484/000121390025016636/ea0231505-def14c_citius.htm) |  | Schedule 14C | <br> A | 02/24/2025 |
| 4.3 | [Bylaws of Citius Oncology, Inc.](http://www.sec.gov/Archives/edgar/data/1851484/000121390024070335/ea021142301ex3-2_citius.htm) |  | 8-K | 3.2 | 8/16/2024 |
| 5.1 | [Opinion of Wyrick Robbins Yates & Ponton LLP.](ea025780301ex5-1_citius.htm) | X |  |  |  |
| 23.1 | [Consent of Wolf & Company, P.C.](ea025780301ex23-2_citius.htm) | X |  |  |  |
| 23.2 | [Consent of Wyrick Robbins Yates & Ponton LLP (included in Exhibit 5.1).](ea025780301ex5-1_citius.htm) | X |  |  |  |
| 24.1 | [Power of Attorney (included on signature page to this Registration Statement on Form S-8).](#a_001) | X |  |  |  |
| 99.1 | [Citius Oncology, Inc. 2023 Omnibus Stock Incentive Plan.](http://www.sec.gov/Archives/edgar/data/1851484/000121390024113150/ea022537201ex10-3_citius.htm) |  | 10-K | 10.3 | 12/27/2024 |
| 99.2 | [Citius Oncology, Inc. 2024 Omnibus Stock Incentive Plan.](http://www.sec.gov/Archives/edgar/data/1851484/000149315224030145/ex10-5.htm) |  | 8-K | 10.5 | 8/5/2024 |
| 99.3 | [Amendment to the Citius Oncology, Inc. 2024 Omnibus Stock Incentive Plan, effective September 19, 2025.](https://www.sec.gov/Archives/edgar/data/1851484/000121390025089615/ea025790901ex10-1_citius.htm) |  | 8-K | 10.1 | 9/19/2025 |
| 107 | [Filing fee table](ea025780301ex-fee_citius.htm). | X |  |  |  |

---

**Item 9. Undertakings.**

(a) The undersigned Registrant hereby undertakes:

&nbsp;&nbsp;&nbsp;&nbsp;(1) To file during any period in which offers or sales are being made, a post-effective amendment to this
Registration Statement:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) To include any prospectus required by section 10(a)(3) of the Securities Act;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) To reflect in the prospectus any facts or events arising after the effective date of the Registration
Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change
in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities
offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or
high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule
424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price
set forth in the Exhibit 107 (Filing Fee Table) in the effective Registration Statement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) To include any material information with respect to the plan of distribution not previously disclosed
in the Registration Statement or any material change to such information in the Registration Statement; *provided, however,* that
paragraphs (a)(1)(i) and (a)(1)(ii) above do not apply if the Registration Statement is on Form S-8, and the information required to be
included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant
pursuant to section 13 or section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective
amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities
at that time shall be deemed to be the initial bona fide offering thereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3) To remove from registration by means of a post-effective amendment any of the securities being registered
which remain unsold at the termination of the offering.

(b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the
Securities Act, each filing of the Registrant's annual report pursuant to section 13(a) or section 15(d) of the Exchange Act (and,
where applicable, each filing of an employee benefit plan's annual report pursuant to Section 15(d) of the Exchange Act) that is
incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities
offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors,
officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised
that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore,
unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses
incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding)
is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless
in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the
question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final
adjudication of such issue.

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Cranford, New Jersey on September 19, 2025.

---

| | |
|:---|:---|
| **Citius Oncology, Inc.** | **Citius Oncology, Inc.** |
| By: | /s/ Leonard Mazur |
|  | Leonard Mazur |
|  | Chief Executive Officer and Chairman |
|  | (Principal Executive Officer) |

---

**POWER OF ATTORNEY**

Each person whose signature appears below hereby constitutes and appoints Leonard Mazur and Jaime Bartushak, or each of them singly, with full power to act without the other, such person's true and lawful attorneys-in-fact and agents, with full power of substitution and re-substitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign this registration statement and any and all amendments, including post-effective amendments to this registration statement, and to file the same, with exhibits and schedules thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary or desirable to be done in connection therewith as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitute or substitutes may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Name** | **Title** | **Date** |
| /s/ Leonard Mazur | Chief Executive Officer and Director | September 19, 2025 |
| Leonard Mazur | (Principal Executive Officer) | September 19, 2025 |
| /s/ Jaime Bartushak | Chief Financial Officer and Treasurer | September 19, 2025 |
| Jaime Bartushak | (Principal Financial Officer and Principal Accounting Officer)) | September 19, 2025 |
| /s/ Myron Holubiak | Secretary and Director | September 19, 2025 |
| Myron Holubiak | Secretary and Director | September 19, 2025 |
| /s/ Suren Dutia | Director | September 19, 2025 |
| Suren Dutia | Director | September 19, 2025 |
| /s/ Eugene Holuka | Director | September 19, 2025 |
| Eugene Holuka | Director | September 19, 2025 |
| /s/ Joel Mayersohm | Director | September 19, 2025 |
| Joel Mayersohm | Director | September 19, 2025 |
| /s/ Dennis McGrath | Director | September 19, 2025 |
| Dennis McGrath | Director | September 19, 2025 |
| /s/ Robert Smith | Director | September 19, 2025 |
| Robert Smith | Director | September 19, 2025 |
| /s/ Carol Webb | Director | September 19, 2025 |
| Carol Webb | Director | September 19, 2025 |

---

## Exhibit 5.1

**Exhibit 5.1**

Wyrick Robbins Yates & Ponton LLP

4101 Lake Boone Trail, Suite 300

Raleigh, North Carolina 27607

September 19, 2025

<br> Board of Directors

Citius Oncology, Inc.

11 Commerce Drive, First Floor

Cranford, New Jersey 07016

**Re:** **Registration Statement on Form S-8**

Ladies and Gentlemen:

We have examined the Registration Statement on Form S-8 filed on or about the date hereof by Citius Oncology, Inc., a Delaware corporation (the "Registrant"), with the U.S. Securities and Exchange Commission (the "Registration Statement"), in connection with the registration under the Securities Act of 1933, as amended, of an aggregate of 45,000,000 shares of common stock, $0.0001 par value per share (the "Shares"). We understand that 15,000,000 Shares are to be issued pursuant to the Registrant's 2023 Omnibus Stock Incentive Plan and 30,000,000 Shares are to be issued pursuant to the 2024 Omnibus Stock Incentive Plan (each referred to individually as the "Plan" and collectively, the "Plans"). In our examination, we have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals and the conformity with the original of all documents submitted to us as copies thereof.

As the Registrant's legal counsel, we have examined the proceedings taken, and are familiar with the proceedings proposed to be taken, in connection with the sale of the Shares pursuant to the Plans.

It is our opinion that, upon completion of the proceedings being taken or contemplated by us, as the Registrant's counsel, to be taken prior to the issuance of the Shares, the Shares when issued in the manner referred to in the Registration Statement and in accordance with the applicable Plan, will be validly issued, fully paid and nonassessable.

We consent to the use of this opinion as an exhibit to the Registration Statement and further consent to the use of our name wherever appearing in the Registration Statement, including the prospectus constituting a part thereof, and any amendments thereto.

---

| |
|:---|
| Sincerely, |
| /s/ Wyrick Robbins Yates & Ponton LLP |

---

## Exhibit 23.1

**Exhibit 23.1**

**Consent of Independent Registered Public Accounting Firm**

We consent to the incorporation by reference in this Registration Statement on Form S-8 of Citius Oncology, Inc. of our report dated December 27, 2024, relating to the consolidated financial statements of Citius Oncology, Inc. appearing in the Annual Report on Form 10-K of Citius Oncology, Inc. for the year ended September 30, 2024.

/s/ Wolf & Company, P.C.

Boston, Massachusetts

September 19, 2025

## Ex-Filing

?xml version='1.0' encoding='ASCII'? Filing Fee Exhibit

**Ex-Filing Fees**

**CALCULATION OF FILING FEE TABLES**

**S-8**

**Citius Oncology, Inc.**

**Table 1: Newly Registered Securities**

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Security Type** | **Security Class Title** | **Notes** | **Fee Calculation<br> Rule** | **Amount Registered** | **Proposed Maximum Offering<br> Price Per Unit** | **Maximum Aggregate Offering Price** | **Fee Rate** | **Amount of Registration Fee** |
| Equity | Common Stock, $0.0001 par value per share | (1) | Other | 45000000 | $1.86 | $83700000.00 | 0.0001531 | $12814.47 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | $83700000.00 |  | 12814.47 |
| Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: |  |  | 0.00 |
| Net Fee Due: | Net Fee Due: | Net Fee Due: | Net Fee Due: | Net Fee Due: | Net Fee Due: |  |  | $12814.47 |

---

**__________________________________________ Offering Note(s)**

&nbsp;&nbsp;&nbsp;&nbsp;(1) Pursuant to Rule 416(a) of the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement also covers any additional shares of Registrant's common stock that become issuable by reason of any stock dividend, stock split, recapitalization, or other similar transaction that results in an increase in the number of outstanding shares of the Registrant's common stock. Consists of 15,000,000 shares reserved for issuance under the Citius Oncology, Inc. 2023 Omnibus Stock Incentive Plan and 30,000,000 shares reserved for issuance under the Citius Oncology, Inc. 2024 Omnibus Stock Incentive Plan. Estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and 457(h)(1) of the Securities Act solely for the purpose of calculating the registration fee based upon the average of the high and low prices of the Registrant's common stock on the Nasdaq Capital Market on September 16, 2025.